The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in
HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral
load.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sharon Riddler
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)